About Nuvesse Skin Therapies
Nuvesse Skin Therapies, fka PolyRemedy, uses Cellulation Technology to deliver higher concentrations of active ingredients where skin needs them most. Each NuvesseMD serum is formulated with a patented trans-epidermal delivery system called Cellulation Technology. Cellulation Technology surrounds and protects key ingredients, transporting higher concentrations of active ingredients to the deeper layers of skin where lasting rejuvenation occurs.
Expert Collections containing Nuvesse Skin Therapies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Nuvesse Skin Therapies is included in 1 Expert Collection, including Beauty & Personal Care.
Beauty & Personal Care
Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.
Latest Nuvesse Skin Therapies News
Mar 9, 2017
Share Article The skin care company has announced a new name to better reflect its presence in the consumer and aesthetic medical markets to Nuvesse Skin Therapies, Inc. The company’s new direction, catalyzed by pH Pharma, Inc.’s majority ownership investment in Nuvesse, as of September 2016, is focused on developing innovative healthcare products for unmet clinical and consumer needs. pH Pharma Inc.is a global healthcare company focused on innovative science and technologies with geographical bases in Silicon Valley for the US market and Seoul for the Asian territories. The Nuvesse Family Look Forward SAN FRANCISCO, CA (PRWEB)March 09, 2017 The skin care company has announced a new name to better reflect its presence in the consumer and aesthetic medical markets to Nuvesse Skin Therapies, Inc. The transition reflects an expansion from their origins in science and wound-healing technology beginning in 2004, when the company originally developed the proprietary wound-healing technology HealSmart™ under the company name PolyRemedy, Inc. Except for the name change, customers and partners will not see any direct impact on the current product line(s) formulated with patented Cellulation™ Technology. It is anticipated new product lines and extensions will be added to the product mix to bolster the company’s offerings, in the near future, to enhance future direction and focus. The company’s new direction, catalyzed by pH Pharma, Inc.’s majority ownership investment in Nuvesse, as of September 2016, is focused on developing innovative healthcare products for unmet clinical and consumer needs. “pH Pharma’s investment in Nuvesse is synergistic with our vision of investing in innovative technologies that provide best-in-class products in focused areas, including dermatology applications. San Francisco, CA and Seoul, Korea traditionally have been leaders in the consumer skin care fields and we intend to build upon that reputation and success.” stated Dr. Hoyoung Huh, Chairman & CEO of pH Pharma and Nuvesse Skin Therapies, Inc. In support of the name change, Nuvesse has also updated their brand identity, which is launching at the same time as their national advertising campaign. About Nuvesse: Nuvesse Skin Therapies, Inc. manufactures and distributes their line of skin care products – serum-infused biocellulose masks and serum rollers – that nourish skin through quality ingredients with two brands, NuvesseMD™ Clinical Skin Therapy sold into the medical aesthetic channel and the consumer brand Nuvesse. Originating in wound healing science, Nuvesse’s patented Cellulation™ Technology helps stimulate the skin’s natural healing process by delivering more key ingredients and essential vitamins deeper into the skin. All of the Nuvesse products can be easily incorporated into a daily skin care regimen to give skin the boost it needs to look rejuvenated and healthier. About pH Pharma: pH Pharma is a global healthcare company focused on innovative science and technologies to develop products with high unmet clinical and market needs. Its leadership team has been involved in the growth of many impactful companies in the healthcare and consumer arenas, including 7 IPOs, 5 M&As and over 20 value-creating partnerships across the US, Europe and Asia. Its major geographical bases are Silicon Valley for the US market and Seoul for the Asian territories, with support from leading international investors and funds. Company Contacts:
Nuvesse Skin Therapies Frequently Asked Questions (FAQ)
When was Nuvesse Skin Therapies founded?
Nuvesse Skin Therapies was founded in 2004.
Where is Nuvesse Skin Therapies's headquarters?
Nuvesse Skin Therapies's headquarters is located at 20980 Redwood Road, Castro Valley.
What is Nuvesse Skin Therapies's latest funding round?
Nuvesse Skin Therapies's latest funding round is Acquired.
How much did Nuvesse Skin Therapies raise?
Nuvesse Skin Therapies raised a total of $54.68M.
Who are the investors of Nuvesse Skin Therapies?
Investors of Nuvesse Skin Therapies include pH Beauty, pH Pharma, MedVenture Associates, Flybridge Capital Partners, Advanced Technology Ventures and 4 more.
Who are Nuvesse Skin Therapies's competitors?
Competitors of Nuvesse Skin Therapies include GENICON, REGENESIS BIOMEDICAL, Acelity, Cohera Medical, Wadsworth Medical Technologies and 7 more.
Compare Nuvesse Skin Therapies to Competitors
Molnlycke Health Care is a manufacturer of single-use surgical and wound care products. The company's products help patients feel less pain and aid healthcare professionals to safer and more efficient surgery.
Regenesis is engaged in the development, manufacturing, and sale of biomedical devices that promote healing and skin wound closure more quickly and cost-effectively than existing standards of wound treatment. The company's devices are based on its Cell Proliferation Induction (CPI) technology, in which electromagnetic signals trigger the repair and regeneration of soft tissue cells.
CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.
Insense Ltd has developed and patented a technology platform centred on the feature of in-situ wound oxygenation. Its first products, Oxyzyme and Iodozyme, target chronic wounds and will be launched into the professional healthcare market.
Developing, manufacturing, selling and exporting transcutaneousndevices which will put physiologically active substances intonsubcutaneous tissue applying the theory of electrophoresis. Developing, manufacturing, selling, exporting and importing cosmetic devices, health enhancement devices and medical devices. nnDeveloping, manufacturing, selling, exporting and importing cosmetics. All businesses that are incidental or related to the businesses stated nin the preceding items.
NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.